SLC5A2 and type 2 diabetes mellitus: In this randomized, controlled trial of the effects of SGLT2 inhibition in addition to loop diuretic in patients with HF with T2D, we found that within 6 weeks empagliflozin caused a significant increase in total urine volume without a significant increase in urinary sodium or FENa compared with placebo.